MOH

EQS-News: Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors

Retrieved on: 
Thursday, December 1, 2022

Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors

Key Points: 
  • Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
    The issuer is solely responsible for the content of this announcement.
  • The Israeli Ministry of Health (MOH) approved a Phase I/II trial of Enlivex Therapeutics Ltd.s (NASDAQ: ENLV) proprietary immunotherapy drug-candidate AllocetraTM.
  • Then, it can turn that macrophage into a pro-tumor ally that will suppress any immune response trying to kill the cancer.
  • The results of early-stage trials may differ significantly from the results of more developed, later-stage trials.

ZICIX AND ASIA BASED CONSTRUCTION GROUP AGREES TO FORM A CONSTRUCTION MANAGEMENT COMPANY

Retrieved on: 
Monday, November 28, 2022

Petty has received a recent report from its ZICIX President, Mr. Fernando M. Sopot that in principle, ZICIX Corporation, and one of Asias largest construction company LA Global Construction and Development, Inc. agrees to merge or join forces together, to form ZICIX-LA GLOBAL Construction Management Group, Inc.

Key Points: 
  • Petty has received a recent report from its ZICIX President, Mr. Fernando M. Sopot that in principle, ZICIX Corporation, and one of Asias largest construction company LA Global Construction and Development, Inc. agrees to merge or join forces together, to form ZICIX-LA GLOBAL Construction Management Group, Inc.
    Construction management is a professional service that provides project owners with effective management of the projects schedule, cost, quality, safety, scope and function.
  • Construction management is compatible with all project delivery methods.
  • No matter the arrangements, ZICIX-LA GLOBAL Construction Management Group is responsible to the Project Owner and to the successful completion of the Project.
  • ZICIXs operating company, CTIP First Investment, Inc. (CTIP-FII), will remain the Project Developer of infrastructure projects awarded to it, and shall be assisted by a Construction Management Company on the daily progress of the work.

AcuCort signs its first commercial agreement for the company's drug Zeqmelit™

Retrieved on: 
Thursday, November 24, 2022

The agreement gives Kamada the exclusive right to the marketing and sales as well as the distribution of AcuCort's drug Zeqmelit for, among other things, the treatment of acute allergy on the Israeli market.

Key Points: 
  • The agreement gives Kamada the exclusive right to the marketing and sales as well as the distribution of AcuCort's drug Zeqmelit for, among other things, the treatment of acute allergy on the Israeli market.
  • Under the terms of the agreement, Kamada is responsible for the commercialization of Zeqmelit in Israel and has the exclusive right to marketing, sales, and distribution of the drug in this market.
  • The agreement is a historic and commercial milestone for AcuCort.
  • It is also a confirmation that AcuCort's innovative drug Zeqmelit is commercially interesting and attracts partners," says Jonas Jnmark, CEO of AcuCort AB.

Bintai Kinden Ventures into Telco through Agreement with MN Permai Netcom

Retrieved on: 
Thursday, November 10, 2022

PETALING JAYA, Malaysia, Nov 10, 2022 - (ACN Newswire) - Bintai Kinden Corporation Berhad (Bursa: BINTAI, 6998), a mechanical and electrical (M&E) engineering services specialist, today announced that the Company's wholly-owned sub-subsidiary, Johnson Medical International Sdn.

Key Points: 
  • PETALING JAYA, Malaysia, Nov 10, 2022 - (ACN Newswire) - Bintai Kinden Corporation Berhad (Bursa: BINTAI, 6998), a mechanical and electrical (M&E) engineering services specialist, today announced that the Company's wholly-owned sub-subsidiary, Johnson Medical International Sdn.
  • (JMI), has formalised a strategic venture with MN Permai Netcom Sdn.
  • Azri Azerai, Executive Director of Bintai Kinden (Download) Azri Azerai, Executive Director of Bintai Kinden said, "This agreement leverages on the strengths of both parties.
  • We also have the expertise in managing large telco infrastructure projects as we were awarded a 120-km fiber optic project in Penang."

Malaysia Seeks Strategic Global Partnerships to Accelerate Its Growth Trajectory As A Preferred Healthcare Destination

Retrieved on: 
Thursday, November 3, 2022

LONDON, Nov. 3, 2022 /PRNewswire/ -- Malaysia Healthcare is strengthening its global proposition for preventive healthcare via strategic partnerships at the World Travel Market 2022 ("WTM") in London. 

Key Points: 
  • LONDON, Nov. 3, 2022 /PRNewswire/ -- Malaysia Healthcare is strengthening its global proposition for preventive healthcare via strategic partnerships at the World Travel Market 2022 ("WTM") in London.
  • Malaysia is a top-of-mind destination for healthcare travellers from around the world and was awarded "Destination of the Year" by UK-based healthcare travel authority International Medical Travel Journal(IMTJ)in 2020.
  • In addition to its commitment to providing affordable, accessible, seamless,and end-to-end quality healthcare, it is also fortifying its healthcare offerings through strategic partnerships with travel agents and healthcare facilitators at regional and global levels.
  • Visit the Malaysia Healthcare booth at the Malaysia Pavilion this 7th to 9thNovember 2022 at World Travel Market atExCel, London, for opportunities to network with representatives from Malaysia Healthcare and explore exclusive healthcare packages.

World Vasectomy Day and DKT International Celebrate 10 Years Inspiring Men to Shoulder Responsibility for Family Planning

Retrieved on: 
Wednesday, October 19, 2022

DKT International , one of the worlds largest providers of family planning, HIV/AIDS, and safe abortion products and services, is proud to continue its support of World Vasectomy Day (WVD) .

Key Points: 
  • DKT International , one of the worlds largest providers of family planning, HIV/AIDS, and safe abortion products and services, is proud to continue its support of World Vasectomy Day (WVD) .
  • DKTs offices around the world will also be supporting the occasion with their events focused on the need for men to shoulder some of the responsibility for family planning.
  • WVD will be in Thailand from November 14-17 during the International Conference on Family Planning (ICFP) alongside DKT International.
  • We thank DKT for its continuous support in growing the World Vasectomy Day movement, adds Jonathan Stack, co-founder of WVD.

HMA conference to look at future of Hospital at Home model in Asia

Retrieved on: 
Wednesday, September 28, 2022

This is why Hospital Management Asia is organising the [email protected] Asia conference, with Singapore's MOH Office for Healthcare Transformation as knowledge partner.

Key Points: 
  • This is why Hospital Management Asia is organising the [email protected] Asia conference, with Singapore's MOH Office for Healthcare Transformation as knowledge partner.
  • The one-day event on 25 November will delve into different aspects of hospital at home programmes with a particular focus on Singapore's [email protected] (Mobile Inpatient Care at Home).
  • Prof Dan and Dr Montalto will be joining the first panel discussion looking at whether Hospital at Home is the future of acute medicine.
  • Registration is now open - click on this link for more information on the agenda, speakers, and to register: www.hospitalmanagementasia.com/events/hospital-at-home/.

Malaysia Diagnostic Labs Market Report 2022: Use of Digital Pathology to Augment Pathological Diagnosis - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 22, 2022

Malaysia diagnostic labs market stood at USD 1011.24 Million in 2021 and is expected to reach a CAGR of 7.89% during the forecast period.

Key Points: 
  • Malaysia diagnostic labs market stood at USD 1011.24 Million in 2021 and is expected to reach a CAGR of 7.89% during the forecast period.
  • According to Novartis Malaysia, non-communicable diseases are responsible for 74% of all fatalities in Malaysia.
  • In the long run, computer-assisted diagnosis (CAD) and personalized care may all be a future of digital pathology.
  • General health check-ups conducted by the government of Malaysia are on the rise, presenting a possible chance of market growth.

Pilot Kidney Exchange Transplant Program Launched Between US, Italy

Retrieved on: 
Friday, September 9, 2022

The Alliance for Paired Kidney Donation (APKD) , an Ohio-based, non-profit organization managing an international kidney exchange registry, today announces the launch of a pilot kidney exchange transplant program between the United States and Italy.

Key Points: 
  • The Alliance for Paired Kidney Donation (APKD) , an Ohio-based, non-profit organization managing an international kidney exchange registry, today announces the launch of a pilot kidney exchange transplant program between the United States and Italy.
  • The new US-Italy program concerns kidney exchange transplantation, in which incompatible living donor and recipient pairs are matched with other incompatible pairs for kidney transplants.
  • Today in the U.S., about 20% of the 6,000 living donor kidney transplants performed are achieved through kidney exchange.
  • This kidney exchange program with the U.S. is the second international exchange program launched by Italy.

Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Retrieved on: 
Wednesday, August 17, 2022

We aim to build on these results in our upcoming Phase I/II trial and are pleased that the Israeli Ministry of Health has cleared it for initiation.

Key Points: 
  • We aim to build on these results in our upcoming Phase I/II trial and are pleased that the Israeli Ministry of Health has cleared it for initiation.
  • The planned Phase I/II trial is a multicenter, open-label, dose escalation trial that is expected to enroll up to 48 patients with advanced solid tumors across two trial stages.
  • Stage 2 will evaluate escalating doses of Allocetra administered IV or IP and combined with anti-PD1 therapy.
  • Patients in Stage 2 will receive three injections of Allocetra concomitantly with the studied anti-PD1 agent.